NVST · Envista Holdings Corporation
$25.45
-1.62% last session
End-of-day data · close of 2026-09-11
Market cap
$4B
Enterprise value
$5B
Trailing P/E
44.6
Forward P/E
15.5
Dividend yield
—
Beta
0.86
Avg volume
3M
Employees
12K
Daily Change %
-1.62%
5 Days Change
-3.15%
10 Days Change
-2.65%
30 Days Change
-7.36%
60 Days Change
1.97%
Month to Day Change
-0.83%
Year to Day Change
21.70%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — NVST
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-09-03
Latest call per bank · past 12 months
JP Morgan
Overweight$32.00
+23.7% vs priceBarclays
Overweight$32.00
+23.7% vs priceMorgan Stanley
Equal-Weight$21.00
-18.8% vs priceCitigroup
Neutral$29.00
+12.1% vs priceWells Fargo
Equal-Weight$26.00
+0.5% vs priceUBS
Neutral$25.00
-3.4% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-03 | JP Morgan | Upgrade | Neutral → Overweight | $29.00 → $32.00 |
| 2026-08-06 | Piper Sandler | Reiterates | Neutral | $26.00 → $28.00 |
| 2026-07-29 | Piper Sandler | Maintains | Neutral | $25.00 → $26.00 |
| 2026-07-09 | BMO Capital | Initiates | Market Perform | $0.00 → $27.00 |
| 2026-06-11 | Barclays | Maintains | Overweight | $34.00 → $32.00 |
| 2026-05-07 | JP Morgan | Maintains | Neutral | $26.00 → $29.00 |
| 2026-05-07 | Evercore ISI Group | Maintains | Outperform | $30.00 → $33.00 |
| 2026-05-07 | Baird | Maintains | Outperform | $30.00 → $31.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 34 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 6.3% below the 50-day MA ($27.16).
- Price vs 200-day MA: Trading 0.0% above the 200-day MA ($25.44).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.23) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($18.95) and high ($30.26).
NVST Price Chart
Loading chart for NVST…
Fundamentals
About Envista Holdings Corporation
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products, as well as provides DTX Studio Clinic, a software package offered with its imaging products. This segment offers its products under the Nobel Biocare, Alpha-Bio Tec, Implant Direct, Nobel Procera, Ormco, Spark, Orascoptic, Damon, Insignia, AOA brands. The Equipment & Consumables segment provides dental equipment and supplies, including digital imaging systems, software, and other visualization/magnification systems; endodontic systems and related products; restorative materials, rotary burs, impression materials, bonding agents, and cements; and infection prevention products. This segment offers its products under the Dexis, DTX Studio, Kerr, Metrex, Total Care, Pentron, Optibond, Harmonize, Sonicfill, Sybron Endo, and CaviWipes to dental offices, clinics, and hospitals. Envista Holdings Corporation was incorporated in 2018 and is headquartered in Brea, California.
More in Medical Instruments & Supplies
ISRG
Intuitive Surgical, Inc.
$129B -37.6% YTD
BDX
Becton, Dickinson and Company
$48B 20.1% YTD
MDLN
Medline Inc.
$44B -18.9% YTD
ALC
Alcon Inc.
$32B -12.8% YTD
RMD
ResMed Inc.
$32B -7.9% YTD
WST
West Pharmaceutical Services, I
$24B 22.8% YTD
SOLV
Solventum Corporation
$15B 13.6% YTD
BAX
Baxter International Inc.
$13B 27.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.